This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Evaluation of Acute Rejection Rates in de Novo Ren...
Clinical trial

Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression

Read time: 1 mins
Last updated:12th May 2014

The purpose of this study is to assess the incidence of acute rejection by 6 months in de novo renal transplant recipients treated with Belatacept following induction therapy with Thymoglobulin, and used in conjunction with adjunct immunosuppression with Mycophenolate Mofetil (MMF) or Everolimus and corticosteroids.

Category Value
Study start date 2014-05-12

View full details